403例非小细胞肺癌组织/细胞中ERCC1、RRM1及β-tubulin Ⅲ的免疫组化和原位杂交检测  

Immunohistochemistry versus in situ hybridization for detecting ERCC1,RRM1 and β-tubulin Ⅲ in 403 non-small cell lung cancer histological and cytological specimens

作　　者：郭燕[1] 谭清和[2] 吉志固[1] 陆俊国[2] 陶玉[1] 陈佳[2] 朱兴华[1] 王建红[2] 杨书云[1] 徐小红[2] 尹海兵[1] 何松[1] 

机构地区：[1]江苏省南通市肿瘤医院病理科,226361 [2]江苏省南通市肿瘤医院内科,226361

出　　处：《江苏医药》2014年第1期27-30,F0002,共5页Jiangsu Medical Journal

基　　金：江苏省卫生厅面上项目(H200867)

摘　　要：目的探讨切除修复交叉互补组基因1(ERCC1)、核糖核苷酸还原酶亚单位M1(RRM1)及β-微管蛋白Ⅲ(β-tubulinⅢ)在非小细胞肺癌(NSCLC)的表达,寻找适合晚期NSCLC的实验材料和检测方法。方法采用免疫组化法对361例组织学标本和42例细胞学标本进行了ERCC1、RRM1及β-tubulinⅢ的检测,分析其表达水平与临床病理参数的关系。其中的85例组织学标本和8例细胞学标本还采用原位杂交法进行了mRNA水平的检测。结果免疫组化检测显示,ERCC1、RRM1及β-tubulinⅢ的阳性率分别为53.8%、46.9%和54.3%。组织学标本与细胞学标本的免疫组化阳性率差异无统计学意义;ERCC1表达与病理类型(鳞状细胞癌阳性率高于腺癌)及淋巴结转移有关,β-tubulinⅢ表达仅与病理类型有关(腺癌阳性率高于鳞状细胞癌),RRM1表达与临床病理参数无关。原位杂交结果显示,ERCC1、RRM1及β-tubulinⅢ的mRNA阳性率分别为39.8%、43.0%和59.1%。结论 ERCC1、RRM1及β-tubulinⅢ的免疫组化检测不仅适用于不同种类的NSCLC组织学标本,也适用于细胞学标本。细胞学标本的mRNA原位杂交法优于免疫组化法。对NSCLC进行这3种基因检测分析,有助于指导术后辅助化疗及晚期患者的个体化治疗。Objective To investigate the expression of excision cross complementation group 1 （ERCC1）, ribonucleotide reductase subunit M1 （RRM1） and class Ⅲ beta-tubulin （β-tubulin Ⅲ ） in different non-small cell lung cancer（NSCLC） specimens and find out materials and methods suitable for the detection of advanced NSCLC. Methods lmmunohistochemistry（IHC） assay was performed in 361 histological and 42 cytological specimens and in situ hybridization was used in the detection of their mRNA in 85 （from 361） histological and 8 （from 42） cytological specimens. The relationship between the expression levels and clinicopathological parameters was analyzed. Results IHC assay showed that the positive rates of ERCC1, RRM1 and Ⅲ-tubulin IH were 53.8%, 46.9% and 54.3%, respectively. The positive rates of histological and cytological specimens by IHC were not significantly different. The expression of ERCC1 was closely related to that of pathological types as well as lymph node metastasis and the expression of β-tubulin Ⅲ was only related to pathological types, while the expression of RRM1 was not significantly ：related to clinicopathological parameters. The expression of ERCC1 was higher in squamous cell carcinoma than that in adenocarcinoma, but the expression of β-tubulin Ⅲ was higher in adenocarcinoma. In situ hybridization examination showed that the positive rates of ERCC1, RRM1 and 13-tubulin Ⅲ were 25.8%//00,26. 9% and 35.5%, respectively. Conclusions Both histological and cytological specimens are suitable for the IHC method to detect ERCC1, RRM1, and βtubulin Ⅲ, while cytological specimens are more suitable for the detection of in situ hybridization. The detection and analysis of these three genes in NSCLC would be helpful in guiding adjuvant chemotherapy for individualized treatment of advanced patients after surgery.

关 键 词：非小细胞肺癌 切除修复交叉互补组基因1 核糖核苷酸还原酶亚单位M1 β-微管蛋白Ⅲ 

分 类 号：R734[医药卫生—肿瘤]